



## The Role of miRNAs in Human Cancer

Guest Editors:

**Dr. Francesca Maria Orlandella**

Dipartimento di Scienze Motorie e del Benessere, Università degli studi di Napoli Parthenope, 80143 Naples, Italy

**Dr. Peppino Mirabelli**

Clinical and Translational Research Unit, Santobono-Pausilipon Children's Hospital, 80129 Naples, Italy

Deadline for manuscript submissions:

**closed (20 December 2024)**

### Message from the Guest Editors

MicroRNAs (miRNAs), a class of highly conserved noncoding RNA, are capable of regulating the expression of several target genes that play a pivotal role in the development and progression of a plethora of pathological conditions. In recent years, knowledge regarding the altered miRNA profile and the biological function of these small molecules in solid cancers and hematologic malignancies are steadily rising. miRNAs act as oncogenes or exert tumor suppressor properties, embodying potential therapeutic targets for the most aggressive form of cancer and leukemia.

The potential application of circulating miRNAs as diagnostic and prognostic biomarkers in liquid biopsy is currently under way, since they are stable and easily detectable in body fluid compared to other current methods. Meanwhile, sensitivity and specificity of isolation and detection miRNA techniques need to be improved.

This Special Issue cordially invites novel studies and review articles that address the peripheral blood miRNA profile to obtain an early tumor detection, thereby improving the diagnostic accuracy, and exploit their potential as novel therapeutic targets for personalized medicine.





*genes*



an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Selvarangan  
Ponnazhagan**

Experimental Cancer  
Therapeutics, The University of  
Alabama at Birmingham, 1825  
University Blvd., SHEL 814,  
Birmingham, AL 35294-2182, USA

## Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

**Journal Rank:** JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))

## Contact Us

---

*Genes* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/genes](http://mdpi.com/journal/genes)  
[genes@mdpi.com](mailto:genes@mdpi.com)  
[X@Genes\\_MDPI](https://twitter.com/Genes_MDPI)